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Abstract The clinical phenotype of human dilated cardio-
myopathy (DCM) encompasses a broad spectrum of
etiologically distinct disorders. As targeting of etiology-
related pathogenic pathways may be more efficient than
current standard heart failure treatment, we obtained the
genomic expression profile of a DCM subtype character-
ized by cardiac inflammation to identify possible new
therapeutic targets in humans. In this inflammatory cardio-
myopathy (DCMi), a distinctive cardiac expression pattern
not described in any previous study of cardiac disorders
was observed. Two significantly altered gene networks of
particular interest and possible interdependence centered
around the cysteine-rich angiogenic inducer 61 (CYR61)
and adiponectin (APN) gene. CYR61 overexpression, as in
human DCMi hearts in situ, was similarly induced by
inflammatory cytokines in vascular endothelial cells in
vitro. APN was strongly downregulated in DCMi hearts
and completely abolished cytokine-dependent CYR61
induction in vitro. Dysbalance between the CYR61 and
APN networks may play a pathogenic role in DCMi and
contain novel therapeutic targets. Multiple immune cell-
associated genes were also deregulated (e.g., chemokine
ligand 14, interleukin-17D, nuclear factors of activated T
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The mesenchymal stem cells protein DSC96 was 4.8-fold (q<0.371)
downregulated in the DCMi group.
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Introduction
The term dilated cardiomyopathy (DCM) describes a
cardiac phenotype characterized by dilation and dysfunc-
tion of the ventricles. From an etiologic perspective, DCM
encompasses a spectrum of disease entities, some of which
are due to monogenic defects in cardiac expressed genes
[1], others triggered by exogenous factors including
cardiotropic viruses [2]. Targeting of etiology-related
pathogenic pathways in etiologically distinct DCM sub-
types may be more efficient than current standard treatment
protocols employed in heart failure of any origin. One
important DCM subtype characterized by cardiac inflam-
mation is designated as inflammatory cardiomyopathy
(DCMi), often found in conjunction with cardiac viral
infections. Spontaneous elimination of cardiac viruses was
associated with significant hemodynamic improvement for
various viruses [3], and interferon-β (IFN-β) therapy was
useful to promote virus elimination and improve cardiac
function and clinical status [4]. A search for new
therapeutic targets in DCMi seems worthwhile due to the
high prevalence of this condition and its still unsatisfactory
long-term outcome. The current study combined in vivo
and in vitro methods to identify possible DCMi-related
gene regulatory networks that might be exploited to expand
the therapeutic repertoire beyond the standard heart failure
drugs currently used. The study does not address individual
gene deregulations, but searches for disturbances of
regulatory gene networks reflected by anomalous cardiac
expression patterns. Genomic screening strategies require
precise phenotyping of the study groups, as this will
minimize interindividual differences and increase the
likelihood of revealing distinctive pathomechanisms. Be-
cause, in advanced stages of DCM, such processes are most
likely overwhelmed by unspecific reactions of the failing
heart long after the initiating process has burnt out, we
investigated patients with moderately severe disease in
contrast to most previous microarray work in the field [5].
The standard clinical characterization was refined by
endomyocardial biopsy (EMB)-based immunohistological
and molecular virological analyses. In contrast to multiple
fields of cancer research, restrictive disease phenotyping of
this kind is rarely employed in cardiovascular research,
mostly due to the difficult access to affected cardiovascular
tissues in humans in vivo. The microarray part of our study
was entirely based on RNA isolated from EMBs thus
providing an approach suitable for follow-up investigations
of clinical courses in relation to cardiac expression profiles.
We report on a distinctive cardiac expression pattern in
DCMi and two significantly altered gene networks centered
around the cysteine-rich angiogenic inducer 61 (CYR61)
and adiponectin (APN) gene.
Patients and methods
Characterization of study groups
The patients investigated by microarray analysis of cardiac
geneexpressiondisplayedthedistinctDCMsubtypeofDCMi
as defined by the World Health Organization and character-
ized by its association with cardiac inflammation. The DCMi
group of this study was derived from a large series of patients
initially submitted to our clinic with symptoms and signs of
DCM; in all of whom, EMBs from the right ventricular
septum were obtained by standard procedure for histological,
immunohistological, and molecular virological analyses. All
patients had given written informed consent. After standard
clinical, morphological, and functional patient characteriza-
tion, their EMBs were assessed for myocardial inflammation
by histological and immunohistological methods. Their
cardiac virological status was assessed by polymerase chain
reaction(PCR)/real-timepolymerasechainreaction(RT-PCR)
for the following viral genomes: enteroviruses, adenoviruses
(ADV), Epstein–Barr virus, human herpesvirus 6 (HHV-6),
and parvovirus B19 (PVB19). Eight DCMi patients with
cardiac inflammation in association with cardiac PVB19 were
selectedforthemicroarraystudy(DCMigroup,Table1). This
group was compared to a control group of four individuals
submitted to our clinic and diagnosed to clarify a clinically
suspected cardiomyopathy, in whom the full differential
258 J Mol Med (2007) 85:257–271diagnostic workup finally revealed that their complaints were
noncardiac in origin (Cont group, Table 1). They had normal
cardiac morphology and function, were negative for cardiac
inflammation or viral genomes, and were subjected to
microarray analysis, too. The DCMi group patients were on
standard heart failure medication and in New York Heart
Association functional class II (Table 1).
High density microarray studies of human cardiac biopsies
cDNA was synthesized from 200 ng of total RNA isolated
from EMBs. The minimal amount of total RNA routinely
available from human EMBs was 200 ng. cRNA targets
were generated using the small sample protocol of
Affymetrix. Briefly, in vitro transcribed unlabeled cRNA
from the first round of amplification was subjected to a
second round of amplification. cRNA was transcribed into
cDNA using random primers. After RNAse H-mediated
removal of surplus cRNA, a second strand was synthesized
using a T7 primer. cRNA amount was determined by
ultraviolet spectroscopy, and distribution of cRNA fragment
sizes of both cRNA and fragmentation products was
checked on a BioAnalyzer. Each cRNA sample was
hybridized for 16 h at 45°C to an Affymetrix Human
Genome U133 Plus 2.0 GeneChip Array. Chips were
washed and stained with streptavidin–phycoerythrin using
a fluidics station according to Affymetrix protocols. Probe
arrays were scanned at 3-/1.56-μm resolution using the
Affymetrix GeneChip System Confocal Scanner 3000. Raw
data were analyzed with Affymetrix GeneChip Operating
Software. The detection p value of a transcript determines
the detection call indicating if the transcript is reliably
detected (p<0.05; present) or not detected (absent). To
enable the comparison between chips, data were normalized
to a global intensity of 500. The expression data can be
obtained from the Gene Expression Omnibus (GEO)
website http://www.ncbi.nlm.nih.gov/projects/geo/,G E O
experimental series number: GSE4172. For TaqMan experi-
ments to verify candidate genes, see next chapter.
Quantitative real-time PCR analysis of human cardiac
biopsies
Total RNAwas extracted using TRIzol reagent (Invitrogen).
Quality and quantity was checked on a Agilent 2100
Bioanalyzer. A minimal amount of only 200 ng of total
RNA was routinely available from human EMBs for cDNA
synthesis to become reverse transcribed using the High
Capacity cDNA Archive Kit (Applied) according to the
manufacturers instructions. For determination of gene
expression, quantitative PCR assays were performed on an
ABI PRISM 7900 Sequence Detector (Applied) with
TaqMan Universal PCR Master Mix and TaqMan Gene
expression assays (Applied) consisting of a FAM™ dye-
labeled TaqMan MGB probe and two PCR primers. The
following oligonucleotide sets purchased from Applied
Biosystems were used: human genes encoding APN
(Hs00605917_m1), CYR61 (Hs00155479_m1), chemokine
ligand 14 (CXCL14; Hs00171135_m1), Ras-responsive
element protein 1 (RREB1; Hs00171486_m1), GTP bind-
ing protein overexpressed in skeletal muscle (GEM;
Hs00170633_m1), membrane protein, palmitoylated 7
(MPP7; Hs00299584_m1), glyceraldehyde-3-phosphate de-
hydrogenase (GAPDH; Hs99999905_m1), and hypoxan-
thine phosphoribosyltransferase 1 (HPRT1; Hs9999
9909_m1). Quantitative RT-PCR reactions were performed
using standard cycle parameters determined by the compa-
ny. Normalization and fold change were calculated with the
Table 1 Characterization of study groups
Code Group Age (years) EF (%) LVEDD (mm) INFLAM PVB19 EV AdV HHV6 EBV
GA-1 DCMi 31 56 71 ++ −− − −
HI-2 DCMi 39 31 61 ++ −− − −
KA-3 DCMi 69 36 60 ++ −− − −
PS-4 DCMi 60 34 76 ++ −− − −
BA-5 DCMi 67 43 59 ++ −− − −
DE-6 DCMi 31 52 57 ++ −− − −
CH-7 DCMi 62 51 73 ++ −− − −
GH-8 DCMi 45 34 62 ++ −− − −
52.5±17 (31–69) 42.0±9.9 (31–56) 62.8±7.8 (57–73)
RS-14 Cont 36 68 47 −− − − − −
SM-15 Cont 46 61 49 −− − − − −
KE-16 Cont 26 74 47 −− − − − −
TU-17 Cont 36 64 50 −− − − − −
36.0±8 (26–46) 66.8±5.6 (61–74) 48.3±1.2 (47–50)
EF ejection fraction; LVEDD left ventricular end-diastolic diameter; INFLAM cardiac inflammation; PVB19 parvovirus B19; EVenterovirus; AdV
adenovirus; HHV6 human herpesvirus 6; EBV Epstein–Barr virus
J Mol Med (2007) 85:257–271 259ΔΔCt method with GAPDH and HPRT1 as reference
mRNA species according to ABI Prism 7900 manufac-
turer’s instructions [6]. The values given in Supplementary
Fig. 2 are the means±SEM of two independent quantitative
TaqMan PCRs performed on RNA isolated from the same
EMB that was also used for the microarray analysis.
Cardiovascular cell cultures
Primary culture of neonatal rat cardiomyocytes (NRCMC):
Cells were prepared from ventricular tissue of 1- to 3-day-
old Wistar rat pups (Charles River) as described previously
[7]. Briefly, the removed ventricles of 50–60 animals were
placed into ice-cold calcium ion-free phosphate-buffered
cell isolation medium (CIM) containing 120 mM NaCl,
Fig. 1 Altered gene expression
profile and regulatory networks
in DCMi. a, c, e The networks
altered in DCMi are displayed
graphically as nodes (genes/
gene products) and edges
(biological relationships be-
tween the nodes). Human,
mouse, and rat orthologs of a
gene are stored as separate
objects in the knowledge base
but are represented as a single
node in the network. The inten-
sity of the node color indicates
the degree of up- (red) or down-
(green) regulation. Nodes are
displayed using various shapes
that represent the functional
class of the gene product. Con-
tinuous edge lines indicate pro-
tein–protein interactions, broken
edge lines changes at the tran-
scriptional level. The software
further displays various labels
that describe the nature of
the relationship between the
nodes (e.g., B for binding, T for
transcription). b, d, f Show
cluster analyses of the genes
within the networks in (a), (c),
(e), respectively. Here, analo-
gous to the networks, red color
denotes upregulation, green
color denotes downregulation of
a gene, whereas the brightness
of the color indicates the extent
of deregulation
260 J Mol Med (2007) 85:257–2714.56 mM KCl, 0.44 mM KH2PO4, 0.42 mM Na2HPO4,
25 mM NaHCO3, and 5.55 mM glucose, pH 7.5, as well as
0.5 mg/ml streptomycin and 5,000 IE/ml penicillin G
(Biochrom). Ventricular tissue was transferred to a Petri
dish and minced into pieces of approximately 1 mm
3 in size
using two sterile scalpels. Stepwise disaggregation for
15 min each of tissue pieces into single cells was performed
at 37°C under continuous mixing with a magnetic stirrer at
150 rpm in a 50 ml Erlenmeyer flask containing 15-ml CIM
supplemented with 0.12% porcine trypsin 1:250 (Belger).
The first tissue digest was discarded. The following three to
eight supernatants obtained after each 15-min digestion
period were poured into single sterile glass centrifuge tubes
each containing 4 ml of ice-cold, heat-inactivated fetal calf
serum (FCS; Biochrom). Cells were gently sedimented at
400 g for 10 min. The sedimented cells were resuspended
in cell growth medium CMRL 1415-ATM (CMRL-ATM,
Connaught Medical Research Laboratories-atmospheric)
that was supplemented with 10% FCS, 10% horse serum
(HS), and 0.02 mg/ml gentamicin (all from Biochrom) and
adjusted to pH 7.4 using 1 N NaOH. For enrichment of
cardiomyocytes, 20 ml of this suspension containing
approximately 1.5×10
8 cardiac cells were incubated in
175 cm
2 plastic dishes, Corning culture flask in a water-
saturated atmosphere for 90 min at 37°C. During this
incubation, most of the nonmuscle cells comprising 30–
40% of total cell number attached to the bottom surface of
the culture flask. The cardiomyocyte-enriched supernatant
was carefully removed and pooled in an Erlenmeyer flask.
The number of cells was counted using a light microscope
and a hemocytometer. The cell density was adjusted with
additional growth medium to 1.2×10
6 cells/ml and the cells
seeded to 6-well Nunc culture plates and incubated in a
water-saturated atmosphere at 37°C. After 24 h of incuba-
tion, the FCS/HS-supplemented growth medium was
replaced either by a 10% FCS-supplemented CMRL
1415-ATM or serum-free, hormone-supplemented CMRL
1415-ATM medium containing 2-μM fluorodeoxfyuridine
(Sigma) for inhibition of proliferation of contaminating
nonmuscle cells. Vascular endothelial cell line:T h e
endothelial cell line EA.hy926 (a hybrid line derived from
human umbilical vein endothelial cells and A549 cells) was
cultured in Dulbecco’s modified Eagle’s medium supple-
mented with hypoxanthine–aminopterin–thymidine, 10%
FCS, and 1% penicillin and streptomycin.
Quantitative real-time PCR analysis of activated cell cultures
To study regulatory factors of CYR61 and APN in cultured
cardiovascular cells (Fig. 2a,b), NRCMCs were grown in 6-
well and EA.hy926 cells in 12-well dishes for 48 h.
Thereafter, they were incubated for 24 h with the following
cytokines (concentrations): IFN-β1b (30 ng/ml), IFN-β1a
(30 ng/ml), IFN-γ (30 ng/ml), IL-1β (30 ng/ml), IL-6
(100 ng/ml), tumor necrosis factor (TNF)-α (20 ng/ml), and
TNF-β (50 ng/ml). In some experiments (Fig. 2a), EA.
hy926 cells were preincubated for 1 h with APN (10 μg/ml)
before the addition of the above cytokines. This APN
concentration was chosen because the APN plasma range in
humans is 3–30 μg/ml. Cells were harvested 24 h after
cytokine addition. Of the total RNA, 1 to 3 μg were isolated
from cell cultures to become reverse transcribed using the
High Capacity cDNA Archive Kit, and TaqMan PCRs were
then carried out employing the following primer systems
(Applied) for the rat genes encoding APN (Acdc,
Rn00595250_m1), CYR61 (Rn00580055_m1), and GAPD
(Rn99999916_s1). mRNA amounts were standardized
against the housekeeping gene GAPDH. The values given
in Fig. 2a,b are the means±SEM of two independent
experiments each performed in triplicate.
Network analysis
The networks shown in Fig. 1a,c,e were derived by the
Ingenuity Pathways Analysis (IPA; http://www.ingenuity.
com) software. The microarray dataset containing gene
Fig. 1 (continued)
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uploaded as an Excel spreadsheet using the template
provided in the application. Each gene identifier was
mapped to its corresponding gene object in the Ingenuity
Pathways Knowledge Base (IPKB). A cutoff of fold change
≥1.5 was set to identify genes whose expression was
significantly differentially regulated; these were then used
as the starting point for generating regulatory networks.
Biological functions were assigned to each network or the
overall analysis, respectively, by using the findings that
have been extracted from the scientific literature and stored
in the IPKB. The biological functions assigned to each
network or the overall analysis, respectively, are ranked
according to the significance of that biological function to
the network or the overall analysis, respectively. A
Fischer’s exact test is used to calculate a p value
determining the probability that the biological function
assigned to that network is explained by chance alone. The
networks are displayed graphically as nodes (genes/gene
products) and edges (the biological relationships between
the nodes). Human, mouse, and rat orthologs of a gene are
stored as separate objects in the knowledge base but are
represented as a single node in the network. The intensity
of the node color indicates the degree of up-(red) or down-
(green) regulation. Nodes are displayed using various
shapes that represent the functional class of the gene
product. Edges are displayed with various labels that
describe the nature of the relationship between the nodes
(e.g., B for binding, T for transcription).
Statistical analysis
For statistical analysis of microarray data, we used the
significance analysis of microarrays (SAM). SAM statistics
identifies significant changes in gene expression by
performing a set of gene-specific t-tests. For each gene, a
score is calculated on the basis of its change of expression
relative to the standard deviation of repeated measurements
for that gene. Genes with scores greater than a given
threshold Δ are defined as significantly deregulated.
Manual adjustment of this threshold Δ allows the identifi-
cation of smaller or larger cohorts of genes. In addition, a
false discovery rate can be estimated based on random
permutations of all measurements. With respect to quanti-
tative TaqMan PCRs, Student’s t-test was applied to
demonstrate statistical significance. A value of p<0.05
was considered statistically significant.
Results
Because, in advanced or end-stage DCM, any etiology-
related pathomechanisms are most likely overwhelmed by
unspecific reactions of the terminally failing myocardium
long after the initiating process has burnt out, we studied
patients with moderately severe disease (Table 1). The
standard clinical characterization was refined by EMB-
based immunohistological (Supplementary Fig. 1)a n d
molecular virological analyses. The DCMi group was
characterized by myocardial inflammation in association
with PVB19. A distinctive expression profile was detected
in the DCMi group by microarray analysis of the EMBs.
The complete dataset is available from the website http://
www.ncbi.nlm.nih.gov/projects/geo/. Genes significantly (q
value<5.0) and ≥1.5-fold deregulated are listed in Supple-
mentary Table 1. Subsequently, a network analysis of the
complete dataset with 380 genes ≥1.5-fold down- and
1,038 genes ≥1.5-fold up-regulated was performed as
shown in Fig. 1a–f. Several of these genes were validated
by quantitative TaqMan PCR (Table 2, Supplementary Fig.
2). Whereas confirmatory PCR analysis was desirable for a
major number of DCMi-associated genes, the limited
mRNA quantity available from human EMBs confined the
number of such analyses. The minimal amount of total
RNA available from EMBs for both microarrays and
confirmatory PCR was only 200 ng. The genes selected
for confirmatory PCRs are shown in Supplementary Fig. 2.
They include CYR61, APN, CXCL14, and GEM as novel
deregulated genes associated with DCMi, natriuretic pep-
tide precursor A (NPPA), and natriuretic peptide precursor
B (NPPB) as standard heart failure-associated genes and
confirmed the microarray data in all cases. The microarray
q values for each of the genes in Supplementary Fig. 2, the
corresponding p values in the confirmatory TaqMan PCRs,
and similar regulatory factors are proof of deregulation of
these genes of particular interest.
The network analysis of the microarray data [8]w a s
conducted by the IPA software employing the genes
significantly (q value<5.0) and ≥1.5-fold deregulated. IPA
is based on modeled biological networks derived from
information of peer-reviewed scientific publications. Analy-
sis of our data revealed several strongly altered regulatory
networks. The gene networks shown in Fig. 1a,c,e have not
been previously described in former microarray studies of
DCM (details in discussion). One of these networks centered
around the CYR61 or CCN1 gene (Fig. 1a,b), another one
around the APN gene (Fig. 1c,d). These networks are related
to cell-to-cell signaling and cellular compromise. Another
network around the AKT1 gene (Fig. 1e,f) also deserves
consideration because AKT1 is involved in the regulation of
both CYR61 [9]a n dA P N[ 10] and because APN strongly
influences CYR61 expression in vitro (Fig. 2b). Table 2
summarizes all member genes of these three networks with
full gene names, q values, and fold changes. Those two
genes (CYR61, APN) that were among the most strongly
deregulated and, at the same time, key components of
262 J Mol Med (2007) 85:257–271complex deregulated networks were further investigated in
cardiovascular cell cultures in vitro (Fig. 2a,b).
The APN regulatory network contains significantly
deregulated (q value≤5.0, ≥1.5-fold change) genes not
previously reported in microarray studies of DCM (full
gene names in Table 1): STAT1 3.0-fold up; JAK2 2.3-fold
up; HBEGF 2.2-fold up; SORT1 2.1-fold up; PTPN11 2.0-
fold up; LPL 1.8-fold up; JAK1 1.6-fold up; SP3 1.6-fold
up; APN 6.8-fold down; INSR 2.5-fold down; PIK3R1 2.5-
fold down; LIFR 2.0-fold down; TNXB 2.0-fold down; and
TGFBR3 2.0-fold down. Three genes encoding the nuclear
factors of activated T cells (NFAT), NFAT1=NFATC2IP
(1.6-fold up), NFAT3=NFATC4 (1.6-fold up), NFAT4=
NFATC3 (1.9-fold up), are also linked to the APN network
as negative regulators of APN expression [11]. Similarly,
the ADIPOR1 gene (1.7-fold up) encoding the APN receptor
1 gene is part of the APN signal transduction system.
A second regulatory network around CYR61 contains
further deregulated genes with q value≤5.0 and ≥1.5-fold
change (full gene names in Table 1): CYR61=CCN1
3.6-fold up; THBS1 3.4-fold up; ITGB1 2.5-fold up;
CD47 2.1-fold up; FGF2 2.1-fold up; NES 2.0-fold up;
PDGFC 2.0-fold up; PTK2 2.0-fold up; BIRC4 1.9-fold
up; HSXIAPA1 1.9-fold up; LAMA2 1.8-fold up; TFPI
1.7-fold up; CXCL14 5.9-fold down; PDGFA 3.6-fold
down; TMSB10 2.6-fold down; EGFR 2.1-fold down;
LAMA4 2.4-fold down; HSPG2 2.1-fold down; TNXB
2.0-fold; and IGFBP5 1.9-fold down. A recent publica-
tion also links CYR61=CCN1 to Wnt signaling pathways
[13] and several Wnt signal pathway genes were deregu-
lated in DCMi: STX16 2.1-fold up; GCLM 2.0-fold up;
CSNK1A1 1.9-fold up; PPP2R1B 1.9-fold up; GSK3B 1.8-
fold up; INSR 2.5-fold down; FBXO40 2.1-fold down; and
CLIC5 2.0-fold down.
In addition to the multifunctional CYR61 and APN
genes, several other deregulated genes are known to be
involved in immunological and inflammatory processes:
The CXCL14 gene was 5.9-fold and the neurturin (NRTN)
gene 5.8-fold downregulated in DCMi. The interleukin-
17D (IL-17D) gene, a member of IL-17A to F gene family,
was 2.6-fold induced. IL-17 serum levels were elevated in
DCMi patients (not shown). Altered intracardiac immune
regulation is further suggested by upregulation of the
immediate early response 3 (IER3, 2.6-fold) and 5 (IER5,
2.3-fold) genes, ubiquitin-specific protease 39 (USP39, 3.4-
fold), phospholipase A2-activating protein (PLAA, 2.6-
fold), and IFN-related developmental regulator 1 (IFRD1,
2.4-fold). Induction of the neural cell adhesion molecule
(NCAM1, 2.0-fold) gene [14] and the coxsackie virus–
ADV-receptor (CXADR, 1.7-fold) gene [15] already known
from immunohistochemical studies of DCMi hearts were
recognized by the microarrays, too.
As a first step to elucidate the molecular mechanisms
that deregulate CYR61 and APN expression in human
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Fig. 2 Cytokines regulating of APN and CYR61 in cardiovascular
cells. We searched for possible triggers of cardiac APN and CYR61
deregulation in DCMi in both endothelial cells and cardiomyocytes.
a, b Summarize real-time quantitative TaqMan PCR data on the
regulatory potential of inflammatory cytokines in these cell cultures
investigated as first approximation to the far more complex in vivo
situation with multiple resident and infiltrating cell types (compare
Fig. 3). a Endothelial cells expressed CYR61 and both APN receptors
but no detectable amount of APN mRNA (data not shown). The
inflammatory cytokines TNF-α and IFN-β induced CYR61 expres-
sion in these cells, whereas others showed no effect (IFN-γ) or even
reduced CYR61 (TNF-β). To reveal possible interactions between the
APN and CYR61 regulatory networks, CYR61 induction experiments
were conducted in the presence (asterisksin shaded bars) vs the
absence of APN. The effect of APN on CYR61 induction by
cytokines was unexpectedly strong: induction of CYR61 by TNF-α
or IFN-β was not only abolished but reverted resulting in a net
reduction of CYR61 expression below that in untreated controls. The
APN concentration at which effect was observed is in the range 3–
30 μg/ml as observed in human plasma [14]. Error bars indicate the
SEM from two independent experiments each performed in triplicate.
b In contrast to endothelial cells, cardiomyocytes expressed APN and
its receptors as well as CYR61. Several inflammatory cytokines (TNF-
α, IFN-β,γ) significantly reduced APN expression in cardiomyocytes,
whereas CYR61 expression was not significantly altered in this cell
type (not shown). Error bars as in panel (a)
J Mol Med (2007) 85:257–271 263Table 2 Partial cardiac gene expression profile of human DCMi (further data at http://www.ncbi.nlm.nih.gov/projects/geo/ and in Supplementary Table 1)
Network Symbol Regulation Factor q value Gene Name
APN APN
a Down 6.8 0.605 Adiponectin
14.4
CYR CXCL14 Down 5.9 1.943 Chemokine (C–X–C motif) ligand 14
4.4
AKT TDGF1 Down 4.7 0.605 Teratocarcinoma-derived growth factor 1
CYR PDGFA Down 3.6 0.371 Platelet-derived growth factor (PDGF)-α polypeptide
APN SOS1 Down 3.1 0.371 Son of sevenless homolog 1 (Drosophila)
CYR TMSB10 Down 2.6 0.371 Thymosin-β10
APN INSR Down 2.5 0.371 Insulin receptor
CYR EGFR Down 2.5 2.226 Epidermal growth factor (EGF) receptor
APN PIK3R1 Down 2.5 0.991 Phosphoinositide-3-kinase regulatory subunit 1 (p85α)
CYR LAMA4 Down 2.4 0.371 Laminin α4
APN LMO4 Down 2.3 3.868 Lin-11, Isl-1, Mec-3 (LIM) domain only 4
CYR HSPG2 Down 2.1 2.226 Heparan sulfate proteoglycan 2
CYR SOX9 Down 2.1 0.371 Sex determining region Y (SRY)-box 9
APN LIFR Down 2.0 1.632 Leukemia inhibitory factor (LIF) receptor
CYR TNXB Down 2.0 0.371 Tenascin XB
AKT TGFBR3 Down 2.0 0.895 TGF-β receptor III (betaglycan)
AKT EIF4EBP1 Down 2.0 2.345 Eukaryotic translation initiation factor 4E binding protein 1
CYR SLIT2 Down 2.0 1.667 Slit homolog 2 (Drosophila)
CYR IGFBP5 Down 1.9 0.991 Insulin-like growth factor binding protein 5
CYR CYR61
a Up 3.6 1.943 Cysteine-rich, angiogenic inducer, 61
3.3
CYR THBS1 Up 3.4 3.868 Thrombospondin 1
APN STAT1 Up 3.0 1.222 Signal transducer and activator of transcription 1
AKT ANKRD1 Up 3.0 2.226 Ankyrin repeat domain 1 (cardiac muscle)
CYR ITGB1 Up 2.5 1.994 Integrin β1=β-subunit of fibronectin receptor (CD29)
AKT BDNF Up 2.4 3.641 Brain-derived neurotrophic factor
AKT MATR3 Up 2.4 0.895 Matrin 3
APN JAK2 Up 2.3 3.469 Janus kinase 2
APN SLC16A1 Up 2.3 1.943 Solute carrier family 16 member 1
APN HBEFG Up 2.2 3.179 Heparin-binding EGF-like growth factor
CYR CD47 Up 2.1 4.108 Integrin-associated signal transducer
CYR FGF2 Up 2.1 2.868 Fibroblast growth factor (basic)
APN SORT1 Up 2.1 1.632 Sortilin
APN EPHA4 Up 2.1 2.345 EPH receptor A4
AKT STX16 Up 2.1 2.226 Syntaxin 16
CYR NES Up 2.0 2.487 Nestin
CYR PDGFC Up 2.0 3.469 Platelet derived growth factor C
CYR PTK2 Up 2.0 1.571 Protein tyrosine kinase 2
APN PTPN11 Up 2.0 1.632 Protein tyrosine phosphatase non-receptor type 11
AKT GOSR2 Up 2.0 1.667 Golgi SNAP receptor complex member 2
APN NFAT4
a Up 1.9 2.345 Nuclear factor of activated T cells 4
CYR BIRC4 Up 1.9 1.943 Baculoviral IAP repeat-containing 4
CYR HSXIAPA1 Up 1.9 2.487 XIAP associated factor-1
AKT PPP2R1B Up 1.9 3.641 Protein phosphatase 2 regulatory subunit A β
APN SMARCA2 Up 1.9 2.226 SWI/SNF related matrix associated regulator of chromatin
AKT MID1 Up 1.9 3.175 Midline 1
AKT PARVA Up 1.8 2.621 Parvin-α
APN LPL Up 1.8 2.487 Lipoprotein lipase
CYR LAMA2 Up 1.8 1.994 Laminin-α2
AKT GSK3B Up 1.8 0.991 Glycogen synthase kinase 3β
AKT PPP2R2A Up 1.8 1.222 Protein phosphatase 2 regulatory subunit B α
APN SYNCRIP Up 1.8 1.994 Synaptotagmin binding RNA interacting protein
AKT PPP2R2A Up 1.8 1.222 Protein phosphatase 2 regulatory subunit B α
AKT UPF3A Up 1.8 3.173 UPF3 regulator of nonsense transcripts A
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were significantly deregulated in DCMi as components of
complex gene networks. Figure 2a shows that certain
inflammatory cytokines induced CYR61 expression in
vascular endothelial cell cultures similarly as observed in
the DCMi hearts. This CYR61 induction by TNF-α and
IFN-β was completely abolished in the presence of APN
(Fig. 2a). The APN plasma range in humans is 3–30 μg/ml
[16], and the concentration therefore chosen for the cell
culture investigations was 10 μg/ml. At this concentration,
APN generally suppressed the CYR61 expression level in
this cell type. In cardiomyocytes, TNF-α, IFN-β, IFN-γ,
and IL-1β all significantly reduced the expression of APN
(Fig. 2b), whereas CYR61 expression was not affected by
these cytokines in this cell type. Several other deregulated
genes of interest known to be involved in immunological
and inflammatory processes were neither expressed in
endothelial cells nor in cardiomyocytes, and therefore could
not be studied in these cell biological models.
Discussion
Identification of DCM subtypes
DCM is the term used to describe any clinical phenotype
characterized by dilation and dysfunction of the cardiac
ventricles. From an etiologic perspective, however, DCM
encompasses a diverse spectrum of disease entities, some of
which are due to monogenic defects in cardiac expressed
genes [1], others triggered by exogenous factors including
cardiotropic viruses [2]. Therapies directed at etiology-
related pathogenic pathways in these etiologically distinct
DCM subtypes may be more efficient than current standard
treatment protocols employed in heart failure of any origin.
However, etiology-related early pathogenic pathways must
be assumed to prevail only in the beginnings of the
respective DCM subtype, whereas common unspecific
molecular pathomechanisms will predominate in advanced
heart failure irrespective of etiology. One important DCM
subtype as defined by cardiac inflammation was investigat-
ed in the current study to further define it at the molecular
level. Whereas previous studies focused on advanced or
end-stage DCM [5] where specific pathomechanisms are
overwhelmed by unspecific processes, we probed an earlier
and restrictively defined phenotype (DCMi) to identify
early and etiology-related disease processes. Importantly,
our patients were not terminally ill nor on maximum
supportive therapy as in previous studies of advanced
DCM. Similarly, controls had no severe underlying condi-
tion as, e.g., heart transplantation donor hearts often used as
controls for expression profiles but were free of cardiac
disease after comprehensive exclusion of multiple cardiac
differential diagnoses. Further, any search for etiology-
Table 2 (continued)
Network Symbol Regulation Factor q value Gene Name
APN ADIPOR1 Up 1.7 2.868 Adiponectin receptor 1
CYR TFPI Up 1.7 3.868 Tissue factor pathway inhibitor
APN SNX1 Up 1.7 4.362 Sorting nexin 1
APN SNX2 Up 1.7 4.467 Sorting nexin 2
APN RBBP4 Up 1.7 2.345 Retinoblastoma binding protein 4
AKT FBXO32 Up 1.7 2.487 F-box protein 32
AKT VPS33A Up 1.7 2.226 Vacuolar protein sorting 33A
APN NFAT1
a Up 1.6 5.091 Nuclear factor of activated T cells 1
AKT NFAT3
a Up 1.6 4.108 Nuclear factor of activated T cells 3
APN JAK1 Up 1.6 1.994 Janus kinase 1
APN SP3 Up 1.6 2.226 Sp3 transcription factor
AKT FRAP1 Up 1.6 4.362 FK506 binding protein 12
AKT STX6 Up 1.6 1.994 Syntaxin 6
CYR PRELP Up 1.6 4.757 Proline arginine-rich end leucine-rich repeat protein
APN RALB Up 1.6 3.173 v-ral simian leukemia viral oncogene homolog B
APN FGF13 Up 1.6 4.757 Fibroblast growth factor 13
APN TGFBR1 Up 1.6 4.108 Transforming growth factor-β receptor I
AKT FTS Up 1.6 3.469 Fused toes homolog
AKT AKT1 Up 1.5 4.757 v-akt murine thymoma viral oncogene homolog 1
AKT PPP2CA Up 1.5 4.362 Protein phosphatase 2 catalytic subunit α
All factors of deregulations are derived from the Affymetrix microarray analysis. For certain genes additional TaqMan analyses were conducted,
which are then given in italics below the respective Affymetrix values (see also Supplementary Fig. 2).
aPlease note the synonyma APN=ADIPOQ, CYR61=CCN1, NFAT1=NFATC2IP, NFAT3=NFATc4, NFAT4=NFATc3
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study groups are highly homogenous. An excellent previ-
ous study has also defined its patient groups by clinical,
morphological, and hemodynamic phenotyping [17] and
derived interesting data on common expression profiles in
disorders linked by common hemodynamic anomalies. We
likewise defined a highly homogeneous study group by
sequential stratification of a large DCM patient cohort, first,
by standard clinical, morphological, and hemodynamic
criteria, second, by biopsy-based detection of cardiac
inflammation in conjunction with a cardiotropic virus.
Cardiac inflammation in our patients was associated with
the presence of PVB19 genomes in the myocardium. We
think, however, that the observed anomalous expression
pattern probably reflects a general inflammatory pathome-
chanism that may be triggered by diverse proinflammatory
stimuli. After the current pilot study all the key genes of
this anomalous pattern need to be further investigated in
major patient groups with varying degrees of cardiac
inflammation and hemodynamic impairment, to address
issues of specificity and dynamic. In vivo biopsies on
which the current study was entirely based further provide
the perspective for follow-up studies of the clinical courses
that would then add a third stratification criterion for patient
selection to be used in the future.
Cardiac expression profile of DCMi
The anomalous cardiac expression pattern observed for
human DCMi was not described in previous studies of
human cardiac diseases or heart failure of any origin [5, 18–
27]. Most network genes listed in Table 2 and, in particular,
CYR61 and APN have, to our knowledge, not been found
to be deregulated in human microarray studies and also not
in animal models of DCM. A comprehensive recent review
[5] summarizes that the major molecular pathway changes
in human DCM, and other human cardiomyopathies
encompass sarcomeric, cytoskeletal, extracellular matrix,
Ca
2+ homeostasis, apoptosis, and energy metabolism genes.
Major deregulations of inflammation- and immune system-
associated genes as in DCMi were not included. Because
we investigated a DCM subtype associated with intracardi-
ac inflammation, a recent microarray study of two giant cell
myocarditis patients [28] is of specific interest for compar-
ison. That study addressed an immunohistologically de-
fined inflammatory cardiac phenotype clearly different
from that in our study and found deregulated T cell
activation genes, including IL-10 receptor-α, β2-integrin,
chemokine receptor 4, and chemokine ligands 5, 9, 13, and
18. Remarkably, none of the latter genes was deregulated in
DCMi but only CXCL14. Conversely, NFAT1 and NFAT4
gene upregulations and APN gene downregulation as
observed in DCMi were not observed in the giant cell
myocarditis study. This appears to reflect distinct immuno-
logical pathomechanisms.
The CYR61 gene and its associated network showed
particularly strong deregulation in DCMi. CYR61=CCN1
is a member of the CCN gene family [29] (also including
connective tissue growth factor [CTGF]=CCN2) and has
already attracted attention as a multifunctional, secreted
protein able to modulate multiple cell functions. It induces
apoptosis in fibroblasts [30] and mediates cell death in
neurons [31] and in virus-infected cells [32]. From a
therapeutic perspective, it is interesting that RNA interfer-
ence-mediated silencing of the CYR61 gene protected cells
against cell death, whereas CYR61 overexpression en-
hanced it [32]. Moreover, CYR61 coordinates genes that
control inflammation (IL-1β), extracellular matrix remod-
eling (e.g., MMP1,3), cell–extracellular matrix interac-
tions, and angiogenesis [33, 34]. CYR61 acts in a cell
type- and context-dependent manner through direct bind-
ing to at least five distinct integrins, including α6β1 and
heparan sulfate proteoglycans as co-receptors [35], integ-
rins αvβ3 and αvβ5 [36], and integrin αMβ2 on blood
monocytes [37]. CYR61 is involved in integrin-linked
kinase-mediated AKT and β-catenin-T cell factor/Lef
signaling [38]. It is also regulated by canonical Wnt
signaling and involved in mesenchymal stem cell differ-
entiation [13]. In contrast to this wealth of data on in vitro
actions of CYR61, data on its physiological functions and
pathogenic potential in humans are sparse. CYR61
upregulation has only recently been described in end-stage
ischemic cardiomyopathy [39]. The current work shows,
for the first time, CYR61 induction in an inflammatory
cardiac disorder with far less severe clinical phenotype,
where, most likely, no irreversible cardiac damage has yet
occurred. Cardiac CYR61 expression is apparently induced
by multiple stimuli [39], including inflammation in vivo
and inflammatory cytokines in vitro (this study). Whereas
transient CYR61 induction may be a temporarily beneficial
response of the heart to various stress factors, chronic
stimulation of the auto/paracrine signaling pathways
activated by CYR61 may be maladaptive and pathogenic
in itself by, e.g., sustaining exuberant tissue inflammatory
and remodeling processes [33]. Our observation of CYR61
overexpression in DCMi suggests to investigate further, if
modulation of CYR61-dependent auto/paracrine pathways
might have therapeutic potential in cardiac diseases
associated with local inflammation.
In the current study, we show, for the first time, that
APN is synthesized by human hearts in situ, not only by
adipose tissues as previously assumed, and that this local
synthesis is strongly downregulated in a human cardiac
disease. Cultured cardiomyocytes were already known to
express APN and both of its receptors and secrete APN
[42]. APN has encountered high interest in the cardiovas-
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proving important functions of APN in the heart [40, 41].
These studies assumed, however, that cardioprotective
effects were exerted by APN synthesized by adipose tissue
and acting via the circulation. APN inhibits apoptosis and
TNF-α production in cardiomyocytes, modulates hyper-
trophic signals in the heart [40], and protects it from
ischemic injury in a mouse model [41]. APN regulation
has not been previously investigated in human hearts in
situ. Previous studies [40, 41] and the present work suggest
that cardiac APN is influenced by multiple factors acting
on components of the APN gene network. AKT1 is
involved in the regulation of both CYR61 [9] and APN
[10]. Interestingly, APN abolished CYR61 induction by
inflammatory cytokines in endothelial cells (Fig. 2a).
Because multiple other endothelial activation markers are
induced in DCMi [54, 55], it is of interest to know the
whole spectrum controlled by APN, but this is beyond the
scope of the current study. In synopsis with a previous
report that APN inhibits IL-8 synthesis by endothelial cells
[10], these data suggest that local cardiac APN synthesis is
required for adequate control of local inflammatory
processes. If so, depression of cardiac APN synthesis by
various mechanism may render the heart vulnerable to
inflammatory challenges such as imposed by infiltrating
immune cells in DCMi or under other conditions associ-
ated with enhanced cardiac inflammatory cytokine produc-
tion [43, 44]. Modulation of the local cardiac APN system
may therefore have therapeutic potential under certain
conditions. Due to the complexities of the biological
functions of both CYR61 and APN, it is impossible to
predict the effects of their modulation in vivo. Synopsis of
previous work and the current study suggests to investi-
gate, however, if modulation of the balance between the
CYR61 and APN networks may have therapeutic potential
in cardiac diseases associated with local inflammation. One
obvious approach would be cardiac APN gene therapy,
another one RNA interference-mediated CYR61 suppres-
sion by cardiac shRNA expression.
In addition to the multifunctional CYR61 and APN
proteins and interacting gene products such as the
NFATs, several other deregulated genes are also directly
involved in immunological and inflammatory processes.
Two genes encoding proteins described as endothelial
activation markers in DCMi [14, 15] were upregulated
2.0-fold (NCAM1) and 1.7-fold CXADR. CXCL14
(a component of the CYR61 network) belongs to a family
of dendritic cell- and monocyte-attracting chemokine-like
proteins [45, 46]. Loss of CXCL14 in tumors was
associated with low infiltration by dendritic cells, whereas
its restoration caused dendritic cell attraction in vitro and in
vivo [47]. The downregulated NRTN gene belongs to the
same family as glial cell line-derived neurotrophic factor
(GDNF). GDNF and NRTN signaling is mediated by a two-
component receptor: the signal-transducing component
RET shared by both ligands and the ligand-specific binding
components GFR-α1 (GDNF) or GFR-α2 (NRTN). Human
T and B cells and monocytes produce RET and NRTN.
GFR-α1 and GFR-α2 are transcribed in all immune cell
subsets, with GFR-α2 being the dominant ligand-binding
chain in T cells, B cells, and monocytes [48]. Therefore,
NRTN downregulation may alter immune cell communica-
tion, whereas little is known about its functions in other cell
types. IL-17D belongs to a family of secreted proteins
that play an active role in inflammatory and autoimmune
diseases [49]. Because IL-17D stimulates production of
IL-6, IL-8, and granulocyte/macrophage colony-stimulat-
ing factor (GM-CSF) in human endothelial cells [50], its
upregulation may enhance the activation of the endothe-
lium, the primary attachment site for migrating immune
cells. IL-17 functionally cooperates with TNF-α [51],
enhances growth of vascular endothelial cells [52], and
stimulates matrix metallo-proteinase-9 expression [53].
The upregulated PLAA activates mammalian PLA2s
involved in inflammatory responses [54]. Thus, PLA2-
IB is upregulated during inflammation, stimulates
CXCL8 production via extracellular signal-regulated
kinase (ERK) and nuclear factor-κB in neutrophils, and
modulates inflammatory responses via the PLA2-IB
receptor [55].
Working model of local cardiac inflammation control
A working model of a novel inflammation-associated
cardiac pathomechanism is outlined in Fig. 3.T h e
model proposes the existence and pathogenic relevance
of a local inflammation control system in human hearts
acting by local synthesis of anti-inflammatory proteins, a
representative of which is APN. If local cardiac APN
synthesis by cardiomyocytes is absent, as in knockout
mice [40, 41], or suppressed, as in DCMi patients,
inflammatory challenges, such as imposed by cardiac im-
mune cell infiltrations (Supplementary Fig. 1), may result
in grave damage to vascular endothelia and myocardium.
The model assumes that cardiac inflammation control is
predominantly mediated by auto/paracrine actions of
locally synthesized APN, whereas, in the context of
cardiac ischemic injury in APN knockout mice, a
complementary systemic model of APN action has been
proposed, in which APN secreted by adipose tissue acts
hormone-like to protect the heart [41] and the endothelia
via the circulation [10]. APN acts directly upon immune
cells, such as natural killer (NK) cells [12], and on
nonimmune cells, such as vascular endothelia [10]. One
new target controlled by APN is CYR61 that is locally
upregulated in DCMi hearts in situ and whose endothelial
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Although CYR61 induces transient local inflammation
and matrix remodeling during healing processes [33], its
activity needs to be controlled so that it does not cause
chronic tissue damage. In addition to such direct anti-
inflammatory actions of APN upon non-immune targets
(endothelial cells, cardiomyocytes), a recent study [12]
shows that APN is also a potent negative regulator of
IL-2-induced NK cell activation. IFN-γ production was
suppressed by APN, accompanied by downregulation of
the IFN-γ-inducible TNF-related apoptosis inducing
ligand and Fas ligands. APN and cellular immunity are
further linked by the fact that NFAT transcription factors
are key regulators of T cell function [56]a n da l s o
negative regulators of APN expression [11]. All local
cardiac functions of CYR61, APN, and other factors in
Fig. 3 Working model of local cardiac inflammation control. The
model proposes the existence of a inflammation control system in
human hearts acting by local synthesis of anti-inflammatory
proteins, a representative of which is APN. If local cardiac
APN synthesis by cardiomyocytes is genetically absent [38, 39]o r
suppressed (this study), inflammatory challenges may result in
aggravated damage to endothelia and myocardium. This local model
assumes that inflammation control and other regulatory functions are
mediated by auto/paracrine actions of APN synthesized locally by
cardiomyocytes, whereas in the context of APN knockout mice [38,
39], a complementary systemic model of APN action was proposed in
which APN secreted by adipose tissue acts hormone-like to protect
heart and endothelia via the circulation. APN (downregulated in
DCMi) acts directly upon immune cells [10]( right side of figure) and
also on nonimmune cells such as vascular endothelia [8]( left side).
One new target for control by APN is CYR61 that is locally
upregulated in DCMi (center) and whose endothelial induction by
cytokines is suppressed by APN (see Fig. 2a). In addition to such
direct anti-inflammatory action of APN on vascular endothelia (left
side), APN is a potent negative regulator of IL-2-induced NK cell
activation (right side)[ 10]. APN and cellular immunity are further
linked by NFATs (upregulated in DCMi), which are key regulators of
T cell function [54], and negative regulators of APN expression [9].
The functions of CYR61, APN, and other factors deregulated in DCMi
in this local model are thought to be mediated via auto/paracrine loops
unrelated to the respective circulating plasma levels. CYR61-associ-
ated CXCL14 downregulation in DCMi (right side) may alter immune
cell attraction to the heart. IL-17D induction in DCMi (left side) may
stimulate IL-6, IL-8, and GM-CSF production by endothelial cells and
thus activation of the endothelium, the primary attachment site for
migrating immune cells
268 J Mol Med (2007) 85:257–271the model are thought to be mediated via auto/paracrine
loops unrelated to the respective circulating plasma levels
(3–30 μg/ml for APN in humans, unknown for CYR61).
Limitations and perspective of the study
Gain/loss-of-function experiments are required to clarify
which of the gene deregulations in DCMi are primary and
causative or secondary and maladaptive. Conventional
gain/loss-of-function experiments in cell cultures may
contribute to solve these questions but are rather artificial
as compared to the complex physiological situation in intact
tissues composed of multiple interacting cell types. Cardiac
overexpression of deregulated genes and silencing of these
genes by shRNA-mediated RNA interference in vivo has
recently become feasible, however, by intravenous injection
of cardiotropic AAV8 and AAV9 vectors in mice [57, 58].
These systems have considerable potential for gene therapy
[59]. Beyond the classical knockout technologies, this
novel approach may also help to clarify pathogenic
cause–effect relationships arising from genomic and pro-
teomic screening studies in humans such as the current one
based on EMBs of human hearts in situ.
Conclusions
Genomic expression profiling evolves as a useful tool to
identify novel pathomechanisms in human cardiac disorders
[5, 8] because most animal models, if available at all,
display multiple crucial differences to the respective human
disease. Restrictive disease phenotyping significantly
improves the chance of genomic approaches to identify
such mechanisms and therapeutic targets even in complex
human disorders. The current work shows, for the first
time, local APN expression in human hearts in situ and its
downregulation in a human cardiac disease. It further
demonstrates that APN efficiently inhibits the endothelial
expression of CYR61 that is strongly induced in DCMi.
Synopsis of previous work and these data suggests to
investigate further, if modulation of the balance between the
CYR61 and APN network may have therapeutic potential
in cardiac diseases associated with inflammation.
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